All News
Urate Lowering Therapy During Acute Gout
Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?
Read Article
Four Lifestyle Changes to Prevent Gout
MedPage Today
JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.
Read Article
Rheums: Got a Rheumatology question or case for RheumNow? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/wzNmOzH4VE https://t.co/6w8CAAUkO6
Links:
Dr. John Cush RheumNow ( View Tweet)
Sign up to attend RheumNow Live--March 20 and 21. CME credits available
https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Links:
Dr. John Cush RheumNow ( View Tweet)
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond.
https://t.co/QisCpdcLEa https://t.co/pZekUvcomE
Links:
Dr. John Cush RheumNow ( View Tweet)
Download your RheumaKnowledgy Card
https://t.co/L7O0UFjEBV https://t.co/iFtVKERnjC
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists: Record your question or case for the RheumNow podcast.
https://t.co/NDhYNX50e2
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us this March for RheumNow Live! Sign up via the link below.
https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI
Links:
Dr. John Cush RheumNow ( View Tweet)
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zJJp8
Links:
Dr. John Cush RheumNow ( View Tweet)
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zs8xA
Links:
Dr. John Cush RheumNow ( View Tweet)
Five Gout Studies Reviewed: Dr. Bella Mehta #ACR20
https://t.co/xTaw4HkD0c https://t.co/904zaAUm1o
Links:
Dr. John Cush RheumNow ( View Tweet)
Content Download Available! Download our document on arthritis myths below.
https://t.co/2Kxpou4Fbz https://t.co/iPIqR92ME1
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR20 Mid Meeting Recap: Gout
https://t.co/MhaYjotrmb https://t.co/R4dOrSlFl6
Links:
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth examines the cardiovascular safety in the FAST trial of Feboxustat at #ACR20.
https://t.co/XCdtWpLKWR https://t.co/BLQdK6tq2s
Links:
Dr. John Cush RheumNow ( View Tweet)
Early view in ACR Open Access:
Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline
https://t.co/QY6pofhamT
ACR_Journals ACR_Journals ( View Tweet)
Four Lifestyle Changes to Prevent Gout
JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.
Read more below.
https://t.co/6eYA75TjPx https://t.co/kLG9ANCxB9
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Ken Saag -- RECIPE Study: MMF with Pegloticase
Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients. #acr20
https://t.co/lpDuahgiVa https://t.co/nb8TqwKP5W
Links:
Dr. John Cush RheumNow ( View Tweet)
Important Gout cohort study of 44 654 US men followed x 26 yrs, shows that 77% of incident gout would have been prevented with thes 4 modifiable risk factors: 1) normal weight, 2) adhere to DASH diet, 3) no alcohol, & 4) no diuretics https://t.co/UsDAN8OykX https://t.co/ivBTb8Nyfw
Links:
Dr. John Cush RheumNow ( View Tweet)
What's New in Calcium Pyrophosphate Disease? NYU's Dr. Michael Pillinger discusses about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at #ACR20.
https://t.co/UDxku4xK0C https://t.co/J661yvO06S
Links:
Dr. John Cush RheumNow ( View Tweet)
